Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday, September 20th.

A number of other equities research analysts have also weighed in on the company. Cantor Fitzgerald restated a “buy” rating and set a $19.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday, September 17th. Mizuho reiterated a “buy” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, August 2nd. LADENBURG THALM/SH SH assumed coverage on Marinus Pharmaceuticals in a research report on Wednesday, June 6th. They issued a “buy” rating and a $20.00 price target on the stock. ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Robert W. Baird assumed coverage on Marinus Pharmaceuticals in a research report on Wednesday, May 23rd. They issued an “outperform” rating and a $15.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Marinus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $19.67.

MRNS stock traded down $0.26 during midday trading on Thursday, reaching $6.28. 782,852 shares of the stock were exchanged, compared to its average volume of 857,183. The firm has a market capitalization of $405.25 million, a P/E ratio of -7.85 and a beta of 2.53. Marinus Pharmaceuticals has a 52 week low of $3.31 and a 52 week high of $10.54.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). On average, sell-side analysts anticipate that Marinus Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $416,000. JPMorgan Chase & Co. acquired a new position in Marinus Pharmaceuticals during the 1st quarter worth approximately $373,000. Trexquant Investment LP acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $102,000. VHCP Management II LLC acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $2,441,000. Finally, GSA Capital Partners LLP acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $141,000. Institutional investors own 63.64% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Recommended Story: Stock Split

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.